BioPharm International, April 2023

The breakthrough approach is commonly used, but the devil is in the details.

In this article, a simple chromatographic model is proposed that is capable of predicting the impact of pH and ionic strength on HIC chromatograms.

The COVID-19 vaccines opened the door to powerful market potential for other nucleic acid-based therapies.

The innovation of going from stainless-steel bioreactors to fixed-bed bioreactors shows an evolution in upstream optimization.

SMB technology in the downstream can facilitate the shift to continuous bioprocessing.

Makers of specialty biologics, gene therapies, and other personalized medicines are working to identify and reduce potential supply chain risks both upstream and downstream.

FDA has spurred investment to create and develop 600 therapies.

What can we take away from Pfizer's acquisition of Seagen?

Direct-to-consumer drug advertising has developed as a cottage industry which has been used to increase prescriptions immensely.